查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1571600

癌症登記軟體市場規模、佔有率、趨勢分析報告：按軟體、按部署模型、按組件、按最終用途、按地區、細分市場預測，2024-2030 年

Cancer Registry Software Market Size, Share & Trends Analysis Report By Software (Standalone), By Deployment model (On-premise), By Component (Commercial), By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

癌症登記軟體市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計2030年全球癌症登記軟體市場規模將達到1.724億美元，2024年至2030年複合年成長率為12.7%。

癌症發生率的增加預計將推動預測期內的成長。癌症目前是全球第二大死因，根據世界衛生組織的數據，約 70% 的死亡發生在低收入和中等收入國家。

此外，已開發國家電子健康記錄(EHR) 的採用率不斷上升，以及對上市後監測的癌症登記的需求不斷成長，預計將在未來幾年進一步推動對癌症登記軟體的需求。市場公司不斷致力於軟體更新，以最大限度地降低安全風險並提供高效的軟體，從而提高市場認知度和採用率。例如，2018年4月，Elekta投資了PalabraApps LLC，以改善其MOSAIQ腫瘤資訊系統軟體。

大型製藥企業進行的臨床試驗數量不斷增加，預計將在預測期內推動市場發展。癌症登記資料可以幫助追蹤患者進行臨床試驗。此外，該軟體還可用於識別某些類型癌症的受影響區域。由於對內部員工的需求減少、成本效益提高以及資源管理高效，大型製藥公司越來越青睞癌症登記軟體，這將進一步推動其擴張。

癌症登記軟體市場報告亮點

  • 獨立軟體佔據市場主導地位，到 2023 年將佔 80.8% 的佔有率。
  • 從部署模式來看，本地部署模式將佔據市場主導地位，到 2023 年將佔據 59.8% 的佔有率。
  • 從組成部分來看，商業細分市場佔據主導地位，2023 年將佔據 75.0% 的佔有率。
  • 政府和第三方部門主導市場，2023年佔27.2%的佔有率。
  • 2023年，北美癌症登記軟體市佔率最大，為44.0%。
  • 預計亞太地區在預測期內將以 14.8% 的複合年成長率成長最快。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章癌症登記軟體市場變數、趨勢與範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 癌症登記軟體市場分析工具
    • 波特的分析
    • PESTEL分析

第4章癌症登記軟體市場：軟體估計和趨勢分析

  • 細分儀表板
  • 癌症登記軟體市場：2023 年和 2030 年軟體變化分析
  • 獨立的
  • 融合的

第5章癌症登記軟體市場：按部署模型進行估計和趨勢分析

  • 細分儀表板
  • 癌症登記軟體市場：2023 年和 2030 年按部署模型分類的變化分析
  • 本地
  • 雲端基礎

第6章癌症登記軟體市場：按組成部分的估計和趨勢分析

  • 細分儀表板
  • 癌症登記軟體市場：2023 年和 2030 年按組件分類的變化分析
  • 商業的
  • 公共

第7章癌症登記軟體市場：最終用途的估計和趨勢分析

  • 細分儀表板
  • 癌症登記軟體市場：2023 年和 2030 年最終用途的變化分析
  • 政府和第三方
  • 私人保險公司
  • 醫院和醫療實踐
  • 製藥生物技術和醫療設備公司
  • 研究所

第8章癌症登記軟體市場：按地區估計和趨勢分析

  • 癌症登記軟體市場佔有率：按地區分類，2023 年和 2030 年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Elekta
    • Oracle
    • ONCO, Inc.
    • IBM
    • MCKESSON CORPORATION
    • Conduent, Inc.
    • Ordinate Corporation
    • Volpara Health Limited
    • Health Catalyst
    • Rocky Mountain Cancer Data Systems（RMCDS）（University of Utah Health）
簡介目錄
Product Code: GVR-3-68038-753-7

Cancer Registry Software Market Growth & Trends:

The global cancer registry software market size is expected to reach USD 172.4 million by 2030, registering a CAGR of 12.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. Growing incidence of cancer is expected to aid growth over the forecast period. Currently, cancer is the second leading cause of death globally, and according to WHO, around 70% of the deaths occur in low- and middle-income countries.

Moreover, rising adoption of Electronic Health Records (EHRs) in developed countries and increasing need for cancer registries for post-marketing surveillance are among the factors further anticipated to boost the demand for cancer registry software in the coming years. Market players are constantly involved in software updation in an attempt to minimize security risks and provide efficient software, thereby increasing market visibility and adoption. For instance, in April 2018, Elekta invested in PalabraApps LLC to improve its MOSAIQ Oncology Information System software.

Increasing number of clinical trials being conducted by major pharmaceutical and biotechnological companies is expected to drive the market over the forecast period. Cancer registry data helps in tracking patients for clinical trials. Moreover, the affected locations for any specific type of cancer can be identified by using this software. Major pharmaceutical companies are increasingly preferring cancer registry software owing to less requirement of internal staff, increased cost-effectiveness, and efficient management of resources, which is further widening the scope for growth.

Cancer Registry Software Market Report Highlights:

  • Standalone software dominated the market and accounted for a share of 80.8% in 2023 attributed to its advanced features and easy-to-use tools.
  • On the basis of deployment model, on-premise model segment dominated the market and accounted for a share of 59.8% in 2023.
  • On the basis of components, the commercial segment dominated the market and accounted for a share of 75.0% in 2023 owing to its advantage of data safety as compared to the public database.
  • The government & third-party segment dominated the market and accounted for a share of 27.2% in 2023.
  • North America cancer registry software market accounted for the largest revenue share of 44.0% in 2023, owing to the presence of developed infrastructure.
  • The Asia Pacific is expected to grow at the fastest CAGR of 14.8% over the forecast period, owing to increasing government initiatives in this region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Cancer Registry Software Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Cancer Registry Software Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Cancer Registry Software Market: Software Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Cancer Registry Software Market: Software Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Standalone
    • 4.3.1. Standalone Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Integrated
    • 4.4.1. Integrated Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Cancer Registry Software Market: Deployment Model Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Cancer Registry Software Market: Deployment Model Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. On-premise
    • 5.3.1. On-premise Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Cloud Based
    • 5.4.1. Cloud Based Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Cancer Registry Software Market: Component Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Cancer Registry Software Market: Component Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Commercial
    • 6.3.1. Commercial Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Public
    • 6.4.1. Public Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Cancer Registry Software Market: End-use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Cancer Registry Software Market: End-use Movement Analysis, 2023 & 2030 (USD Million)
  • 7.3. Government & Third Party
    • 7.3.1. Government & Third-Party Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Private Payers
    • 7.4.1. Private Payers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Hospital & Medical Practice
    • 7.5.1. Hospital & Medical Practice Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Pharma Biotech & Medical Device Companies
    • 7.6.1. Pharma Biotech & Medical Device Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Research Institutes
    • 7.7.1. Research Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Cancer Registry Software Market: Regional Estimates & Trend Analysis

  • 8.1. Cancer Registry Software Market Share, By Region, 2023 & 2030, USD Million
  • 8.2. North America
    • 8.2.1. North America Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. U.S. Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.3. Canada
      • 8.2.3.1. Canada Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.4. Mexico
      • 8.2.4.1. Mexico Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. UK Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.3. Germany
      • 8.3.3.1. Germany Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. France Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Italy Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Spain Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Denmark Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Sweden Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Norway Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Japan Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. China
      • 8.4.3.1. China Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. India Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.5. Australia
      • 8.4.5.1. Australia Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.6. South Korea
      • 8.4.6.1. South Korea Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.7. Thailand
      • 8.4.7.1. Thailand Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Brazil Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Argentina
      • 8.5.3.1. Argentina Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Middle East and Africa
    • 8.6.1. Middle East and Africa Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. South Africa Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Saudi Arabia Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. UAE
      • 8.6.4.1. UAE Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Kuwait
      • 8.6.5.1. Kuwait Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis by Key Market Participants
  • 9.2. Company Categorization
  • 9.3. Company Heat Map Analysis
  • 9.4. Company Profiles
    • 9.4.1. Elekta
      • 9.4.1.1. Participant's Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Recent Developments/ Strategic Initiatives
    • 9.4.2. Oracle
      • 9.4.2.1. Participant's Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Recent Developments/ Strategic Initiatives
    • 9.4.3. ONCO, Inc.
      • 9.4.3.1. Participant's Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Recent Developments/ Strategic Initiatives
    • 9.4.4. IBM
      • 9.4.4.1. Participant's Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Recent Developments/ Strategic Initiatives
    • 9.4.5. MCKESSON CORPORATION
      • 9.4.5.1. Participant's Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Recent Developments/ Strategic Initiatives
    • 9.4.6. Conduent, Inc.
      • 9.4.6.1. Participant's Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Recent Developments/ Strategic Initiatives
    • 9.4.7. Ordinate Corporation
      • 9.4.7.1. Participant's Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Recent Developments/ Strategic Initiatives
    • 9.4.8. Volpara Health Limited
      • 9.4.8.1. Participant's Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Recent Developments/ Strategic Initiatives
    • 9.4.9. Health Catalyst
      • 9.4.9.1. Participant's Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Recent Developments/ Strategic Initiatives
    • 9.4.10. Rocky Mountain Cancer Data Systems (RMCDS) (University of Utah Health)
      • 9.4.10.1. Participant's Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Recent Developments/ Strategic Initiatives